Procyon Corp (PCYN) Stock Price & Analysis
Procyon Corp (PCYN) rose 0.00% to USD 0.2 as of June 10, 2026 at 11:47 UTC, according to Nexqual real-time market data.
PCYN last closed at USD 0.2; the session ranged USD 0.2–0.2 on volume of 10,000 shares. Market capitalization is $1.64M, with a 52-week range of USD 0–0.28 (PNK). Source: Nexqual, June 10, 2026 at 11:47 UTC.
Key Statistics (as of June 10, 2026 at 11:47 UTC)
| Price | USD 0.2 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.2 |
| Open | USD 0.2 |
| Day Range | USD 0.2 – 0.2 |
| 52-Week Range | USD 0 – 0.28 |
| Volume | 10,000 shares |
| Market Cap | $1.64M |
| Exchange | PNK |
Technical Analysis (PCYN)
Nexqual's technical model rates PCYN "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 11:47 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 0 (oversold) |
| vs SMA50 | Below (USD 0.23) |
| MACD | -0 (negative) |
Analyst Ratings (PCYN)
Wall Street analysts rate PCYN "None", per Nexqual as of June 10, 2026 at 11:47 UTC.
| Consensus Rating | None |
|---|
Earnings (PCYN)
Source: Nexqual, June 10, 2026 at 11:47 UTC.
Financials & Fundamentals (PCYN)
| Total Revenue | $4.98M |
|---|---|
| Revenue Growth (YoY) | +17.50% |
| Gross Margin | +78.07% |
| Operating Margin | +0.63% |
| Profit Margin | -6.84% |
| ROE | -13.91% |
| Debt / Equity | 18.66 |
| Current Ratio | 3.08 |
| Total Cash | $908,820 |
| Total Debt | $426,718 |
| Free Cash Flow | $-49,208 |
Source: Nexqual, June 10, 2026 at 11:47 UTC.
Financial Health Score (PCYN)
Nexqual rates Procyon Corp's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 11:47 UTC.
| Growth | Strong — Revenue +18% YoY (latest Q) |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $909K cash, no debt |
| Cash Flow | Weak — FCF negative: -$49K, burning cash |
| Efficiency | Critical — ROE -14%, ROA -4.3% |
Ownership (PCYN)
| Insider Ownership | +64.47% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 8.14M |
| Float | 4.29M |
Source: Nexqual, June 10, 2026 at 11:47 UTC.
Leadership (PCYN)
Procyon Corp is led by Justice W. Anderson (age 48), CEO, President & Director, per Nexqual as of June 10, 2026 at 11:47 UTC.
| CEO, President & Director | Justice W. Anderson (age 48) |
|---|---|
| CFO & Director | James B. Anderson (age 55) |
| Vice President of Sales - Amerx Health Care Corp. | George Otis Borak (age 64) |
From Procyon Corp's Latest SEC 10-K Filing (filed 2024-10-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Procyon Corporation, together with its subsidiaries, manufactures and markets wound and skin care products primarily in the United States.
- The company also offers AMERIGEL hand sanitizer; EXTREMIT-EASE compression garment products; Advantagen, a surgical collagen powder that promotes wound closure and reduces the potential for surgical site infection; calcium alginate, foam, and gauze dressings; retention tapes; and helix collagen gel.
- It sells its products to institutional customers such as hospitals, wound care clinics, skilled nursing facilities, home health agencies, physicians, and other health care practitioners; and retail customers through distributors, and direct and internet sales, as well as through independent and retail chain drug stores.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ECIA | Encision, Inc. | USD 0 | ▲ 0% |
| RBCL | RBC LIFE SCIENCE INC | USD 0 | ▲ 0% |
| QMDT | QUICK-MED TECHNOLOGIES INC | USD 0 | ▲ 0% |
| IEHC | IEH Corp. | USD 19.83 | ▲ 1.41% |
| IVRO | InVitro International | USD 0.08 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 11:47 UTC. This page is informational and not investment advice.